Curis (NASDAQ:CRIS) Shares Cross Above 50 Day Moving Average – Time to Sell?

Shares of Curis, Inc. (NASDAQ:CRIS) crossed above its 50-day moving average during trading on Wednesday. The stock has a 50-day moving average of $0.88 and traded as high as $1.60. Curis shares last traded at $1.1140, with a volume of 162,381,274 shares traded.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on CRIS shares. Weiss Ratings restated a “sell (e+)” rating on shares of Curis in a report on Thursday, October 15th. Wall Street Zen raised Curis from a “strong sell” rating to a “hold” rating in a report on Saturday, August 22nd. Zacks Research raised Curis from a “strong sell” rating to a “hold” rating in a report on Wednesday, September 9th. Finally, HC Wainwright reiterated a “buy” rating on shares of Curis in a research report on Monday, August 17th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Curis has a consensus rating of “Hold” and an average price target of $43.00.

Curis Stock Performance

The stock has a 50-day simple moving average of $0.85 and a 200-day simple moving average of $8.65.

Curis (NASDAQ:CRIS) last posted its quarterly earnings results on Friday, August 14th. The biotechnology company reported ($4.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($6.95) by $2.93. As a group, equities research analysts forecast that Curis, Inc. will post -15.65 EPS for the current year.

Institutional Trading of Curis

Several hedge funds and other institutional investors have recently modified their holdings of CRIS. Focused Wealth Management Inc acquired a new position in Curis in the 2nd quarter valued at approximately $26,000. BlackRock Inc. acquired a new stake in shares of Curis in the second quarter valued at approximately $28,000. Renaissance Technologies LLC boosted its holdings in Curis by 52.2% in the first quarter. Renaissance Technologies LLC now owns 366,740 shares of the biotechnology company’s stock valued at $201,000 after acquiring an additional 125,823 shares during the last quarter. Flputnam Investment Management Co. bought a new stake in shares of Curis during the second quarter worth approximately $128,000. Finally, Cable Car Capital LP acquired a new stake in shares of Curis during the second quarter worth $696,000. 29.97% of the stock is currently owned by hedge funds and other institutional investors.

Curis Company Profile

Curis, Inc is a clinical-stage biotechnology company focused on developing innovative therapeutics for the treatment of cancer. The company’s research and development activities center on targeted therapies designed to address biological pathways involved in tumor growth and immune regulation.

Curis’ lead investigational product is emavusertib, an oral inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). The company has evaluated emavusertib in clinical studies for hematologic malignancies, including acute myeloid leukemia, myelodysplastic syndromes and certain forms of non-Hodgkin lymphoma.